A Safety and Tolerability Study of Denufosol in 2-4 Year Olds

Key facts

Sponsor

Merck Sharp & Dohme LLC

Principal Investigator

Lynn Smiley, MD

Medical monitor

Intervention

denufosol tetrasodium Inhalation Solution(drug)

Enrollment

25 enrolled

Eligibility

2-4 years · All sexes

Timeline

2010 – 2010

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cystic fibrosis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT04530383
  Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function
  University of Kansas Medical Center
• RECRUITINGPHASE2NCT07450547
  Phase 2 Study to Assess the Safety and Efficacy of ANG003
  Anagram Therapeutics, Inc.
• RECRUITINGPHASE1NCT07437105
  Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
  Vertex Pharmaceuticals Incorporated
• RECRUITINGNANCT07436351
  ACT With CF Self-Help Toolkit
  Thomas Jefferson University
• RECRUITINGNCT07083557
  Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
  Bettina Mittendorfer
• RECRUITINGNANCT07314229
  Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor
  University Hospital, Lille
• RECRUITINGNCT07369414
  Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at Home
  Research Center Borstel
• RECRUITINGNCT07505797
  ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)
  iSono Health, Inc.

See all trials for Cystic fibrosis →